The achievement of CR is the crucial step for a prolonged PFS and OS after an autologous SCT in multiple myeloma (MM). Unfortunately, even with the use of new regimens and the current high CR rates, most, if not all, patients will ultimately relapse or progress. We analyzed the type of relapse or progression (asymptomatic vs symptomatic), clinical features including the presence of extramedullary involvement and time to next treatment in 211 patients who underwent melphalan-based autologous SCT over an 18-year period at our institution. After autologous SCT, serological or asymptomatic relapse/progression was observed in about one half of the patients. The treatment-free interval was significantly longer in patients relapsing from CR than in those progressing from PR (P ¼ 0.017). Patients with serological relapse/progression had a significantly longer OS than those relapsing from symptomatic disease (P ¼ 0.002). The relapse pattern was similar to the initial clinical presentation. Survival after relapse/progression was shorter in those patients with a 24-h urine M-protein excretion of at least 200 mg (P ¼ 0.048). Extramedullary involvement was frequent (24%), being the highest risk in patients with extramedullary involvement at diagnosis (P ¼ 0.001).
INTRODUCTION
Multiple myeloma (MM) is the prototype malignant plasma cell disorder. 1 High-dose therapy followed by autologous SCT is the gold standard as first-line treatment in young patients with this disease. 2 This procedure is responsible, at least in part, for the improved prognosis in patients with MM in recent years, 3 resulting in an increased CR rate, prolonged PFS and potential cure of a small fraction of patients. 2 The achievement of CR is the crucial step for a prolonged PFS and OS after autologous SCT in MM, 2 and the sensitivity to the initial therapy measured by the M-protein size at the time of transplantation is the most important predictor of CR after autologous SCT. 4, 5 Eventually, all patients not achieving CR after autologous SCT will develop progressive disease and only onethird of those achieving CR will remain in continued CR beyond 10 years after ASCT. 6 Despite the extremely high rate of relapse/progression after autologous SCT, the studies on its pattern are limited. From the available data, it seems that at the time of relapse/ progression, the pattern of relapse can be very heterogeneous. 7 Thus, while a number of patients can show only an M-protein increase, without clinical manifestation, 8 others can develop more aggressive progression including lytic lesions and/or anemia, extramedullary plasmacytomas (EMP) or secondary plasma cell leukemia (PCL), requiring immediate treatment. The aim of this study was to investigate the characteristics at the time of relapse or progression in patients with MM who received autologous SCT as part of their first-line treatment at a single institution.
PATIENTS AND METHODS Patients
From 31 March 1994 to 27 December 2011, 211 patients underwent melphalan-based autologous SCT at our institution. Of these, 170 patients with chemosensitive disease (87M/83F, median age 56 years, range 25-70) who achieved at least a minimal response (MR) after no more than two induction lines before autologous SCT are the basis of this study. The demographics and disease features at the time of diagnosis are summarized in Table 1 . The clinical and laboratory data at the time of relapse/progression, as well as the information concerning treatment and follow-up, were collected.
A total of 113 patients (66.5%) received induction with conventional chemotherapy, while 56 (32.9%) were initially treated with regimens incorporating novel agents. One patient underwent autologous SCT without previous cytoreductive treatment. The induction regimen more frequently used in the first group was alternating polychemotherapy (74%) V[B]CMP (vincristine, [BCNU] , melphalan, CY, prednisone) and VBAD[P] (vincristine, BCNU, doxorubicin, dexamethasone [prednisone]), VAD (8.8%); CY and dexamethasone (8%) or other combinations (9.2%). In the second group, the induction regimen was based on combinations of glucocorticoids with bortezomib (57.1%; including VBCMP/VBAD in eight patients), thalidomide (28.6%), or with bortezomib plus thalidomide (14.3%). All patients achieved at least MR previous to autologousSCT (15.9% CR, 70.6% PR and 13.5% MR), after one (83.5%) or two (16.5%) induction regimens prior to melphalan-based autologous SCT. Second regimens were administered because of lack of response to the first-line chemotherapy and resulted in at least MR before autologous SCT in all cases. Cytogenetics/FISH analysis was available only in 58 patients, including 7 patients with t(4;14), 13 with t(11;14), 1 with t(14;16) and 7 with del17p. Seventy-three patients (42.9%) received maintenance therapy after autologous SCT. The maintenance regimens consisted of interferon alpha-2b with or without glucocorticoids (76.6%), thalidomide as single agent (12.4%) and thalidomide plus bortezomib (11%). The median duration of maintenance therapy was 3 years (range 1 month to 18 years).
When relapse or progression after autologous SCT was observed, the type of relapse or progression (asymptomatic vs symptomatic), laboratory characteristics, presence of bone or extramedullary involvement, time to next treatment, reason for anti-myeloma therapy and salvage regimen were recorded. Serum-free light chain was not available in a systematic manner for historical reasons. Patients were followed systematically every 2 months during the first 2 years, once clinical and hematological recovery was reached, and every 3 months beyond the third year after autologous SCT according to our local clinical guidelines. Extramedullary plasmacytoma was defined as soft-tissue mass originating from contiguous bone or due to hematogenous spread. 9 The median follow-up for alive patients was 3.9 years (range 4 months to 18 years). No patient was lost to follow-up. Response, relapse and progression were defined according to the European Blood and Marrow Transplantation (EBMT) criteria. 10 In short, CR required the disappearance of the original myeloma protein in serum and urine immunofixation (IFE) and less than 5% bone marrow plasma cells (BMPCs). PR required a serum M-protein decrease of 50% or more and a urine M-protein decrease of 90% or more, and/or to o200 mg/24 h as well as a reduction in 50% or more in the cross-sectional areas of extraosseous plasmacytomas. In patients with PR, an increase of 450% for the lowest M-component level previously achieved was required to consider progression. In patients with CR, relapse was defined by the recurrence of a detectable M-component on immunofixation, even if electrophoresis remained negative, excluding oligoclonal immune reconstitution. Asymptomatic or serologic relapse progression was defined as the biochemical relapse from CR or progression from PR in serum and/or urine, in the absence of clinical manifestation (CRAB criteria and/or extramedullary disease). The Ethics Committee of Hospital Clínic of Barcelona provided institutional review board approval for this study.
Statistical analysis
Statistical differences among the subgroups of patients were compared by using the w 2 test (two-tailed), the Student's t-test or non-parametric tests when necessary. PFS was defined as survival from autologous SCT until relapse or death from any cause. OS was calculated from the time of autologous SCT to last follow-up or death. Survival probabilities were estimated using the Kaplan-Meier method and analyzed by means of the log-rank test. Cox proportional hazards model was used to estimate the risk ratio of events (ORR) with the respective confidence interval (CI) after controlling for prognostic variables in multivariate analysis. Statistical tests were performed with PASW software 18.0 for Windows (Chicago, IL, USA). A P value of o0.05 was required for statistical significance.
RESULTS

Asymptomatic versus symptomatic relapse/progression
After autologous SCT, median PFS was 3.3 years (CI 95% 2.7-3.9 years) and the median OS of 6.8 years (CI 95% 3.9-9.6 years). Only 76 of the 170 patients (47.7%) had achieved a CR. As of December 2011, 93 patients (54.7%) had relapsed or progressed after autologous SCT. In the overall relapsed/progressed population, the median time to next treatment was only 2 months (range 0-5.6 years). Only 37 out of the 93 patients (40%) had relapsed from CR, while the remaining 60% had progressed from PR. There was a trend toward a significantly longer OS for patients relapsing than those progressing (P ¼ 0.073) (Figure 1) . A serological or asymptomatic relapse/progression was as frequent as a symptomatic one (49.5% vs 50.5%, respectively), the latter requiring immediate treatment in a median of one month. There was no difference in evaluation intervals after autologous SCT between patients with serological and symptomatic relapse/progression (6.42 vs 5.74 per year, respectively, P ¼ 0.271). The group with symptomatic relapse/progression showed a higher BM plasma cell infiltration at diagnosis (67 vs 38%; P ¼ 0.01), anemia (48.9 vs 26.1%; P ¼ 0.02) and a more advanced ISS stage (ISS 3; 34.1 vs 7.1%, P ¼ 0.001), than those with an asymptomatic one. Asymptomatic relapse was less frequent before 2000 than in more recent years (26.3 vs 55.4%; P ¼ 0.024). Other variables, including age, heavy-chain isotype involved, Durie-Salmon stage, presence of EMP, hypercalcemia or renal insufficiency at diagnosis were quite similar between these two groups. There was no difference in the incidence of asymptomatic relapse/progression according to the use of maintenance therapy after autologous SCT (50 vs 48.9%; P ¼ 0.915). Patients with serological relapse/progression had a significantly longer OS than those relapsing with a symptomatic disease (P ¼ 0.002) (Figure 2 ). Only one patient (1.1%) relapsed with a plasma cell leukemia picture.
Clinical features
The main clinical reasons to start myeloma therapy were anemia (43%), new bone lytic lesions (36%), EMP (23.7%), bone pain (14.4%), renal insufficiency (12.2%) and/or hypercalcemia (9%). Among the 11 patients who developed renal insufficiency at relapse/progression, 6 (54.5%) had renal function impairment at diagnosis. The rate of this complication at relapse/progression was associated with the presence of renal insufficiency at diagnosis (P ¼ 0.003). A similar correlation was also observed between hypercalcemia at relapse/progression and the presence of hypercalcemia at the time of diagnosis (P ¼ 0.03).
Urine protein studies Patients with symptomatic relapse/progression showed a significantly higher amount of both total 24 h proteinuria (median 404 vs 155 mg; P ¼ 0.02) and urine M-protein excretion (median 155 vs 0; P ¼ 0.002) than those with asymptomatic progression. Interestingly, 17 out of 93 patients had a urine M-spike higher than 500 mg/24 h at relapse/progression. Of note, 12 of them (70.6%) had also a similar amount at the time of diagnosis, showing a significant correlation between both values (P ¼ 0.001). Survival after relapse/progression was shorter in those patients with a 24-h urine M-protein excretion of at least 200 mg (P ¼ 0.048). Thirteen patients relapsed/progressed in urine without any monoclonal protein in serum; eight had only light-chain myeloma at diagnosis while the remaining five were four IgG and one IgA, all with some degree of light chain in urine at diagnosis 
1).
The median time between asymptomatic relapse or progression and treatment was only 5.6 months (range 0-5.6 years). However, in 12 out of 46 patients (26%) with asymptomatic relapse/ progression treatment was not initiated within the first 2 years. All these 12 patients had an ISS I or II at diagnosis, the M-protein type was IgG in 58% of the patients, and only one had extramedullary involvement. Other clinical features of aggressiveness at diagnosis, such as renal failure, hypercalcemia or anemia, were present in only one, one and three cases, respectively. All patients had received combination chemotherapy, with no novel agents at induction pre-autologous SCT, except for one treated with bortezomib/dexametasone. Median OS after relapse/progression in this group was 8.5 years, with only four deaths. Three of these 12 patients had not received any rescue therapy at 2, 3 and 4 years from relapse. In asymptomatic patients, this pattern of 'slow' progression was more frequent in relapsed (36.4%) than progressing patients (16.7%), but without statistical significance (P ¼ 0.129). Finally, time to next treatment was significantly longer in patients relapsing from CR (median 2.85 years; CI 95% 2.1-3.6) vs those progressing from PR (median 1.65 years; CI 95% 1.1-2.2) (P ¼ 0.017).
Univariate and multivariate analysis for OS after relapse/ progression are shown in Table 2 . The only significant variables associated with OS at the multivariate analysis were time to relapse, the type of relapse (asymptomatic vs symptomatic) and use of salvage second autologous or allogeneic SCT. This last one is certainly controversial, as a number of important factors may influence the indication and/or feasibility of a second SCT, such as age, performance status, sensitivity to treatment at the time of progression and time from autologous SCT to relapse. In fact, among the 93 patients, there were only 18 cases who underwent salvage SCT (11 autologous and 7 allogeneic).
DISCUSSION
The beneficial effect of autologous SCT likely results from the higher tumor reduction achieved, as compared with that attained with conventional chemotherapy. 11, 12 With the use of induction regimens based on conventional chemotherapy, the post-transplantation CR rate was between 30 and 35% and the median survival B6 years. 3, 13 The incorporation of novel drugs (thalidomide, lenalidomide and, particularly, bortezomib) into induction therapy has improved the pre-and post-transplant CR rate and the PFS, when compared with previous results. 2 It seems evident that triple induction regimens such as VTD (bortezomib/thalidomide/dexamethasone) results in a higher post-transplantation CR rate with a significant PFS prolongation.
14 Furthermore, post-transplantation consolidation and maintenance with novel agents will likely become another important step forward. 15 Unfortunately, even with these high CR rates, most, if not all, patients will ultimately relapse or progress and at the time of relapse from CR or progression from PR clinical patterns are considered very heterogeneous. Some authors consider that the relapse/progression picture is completely different from the clinical presentation of the disease. 7, 16 As the first point of discussion, our results from a long-term, single-center experience show that the disease characteristics at relapse resemble those observed at the time of diagnosis. Thus, it is of interest that in patients presenting with light-chain protein excretion, the first indication of relapse was the reappearance of the light chains in urine. Similarly, renal insufficiency and hypercalcemia were most frequent in those who developed them initially. In our experience, the 'light-chain urine escape' or shift in secretion from intact Ig to light-chain-only secretion 17 is uncommon. Thus, no patient without light-chain proteinuria at diagnosis relapsed or progressed with only the urine light chain criterion. Light-chain urine protein measurements at relapse/progression were crucial, particularly in patients with M-spike in the urine at diagnosis. In contrast to some recent observations, 18 sequential measurement is very helpful and we strongly recommend that the 24-h-urine light-chain protein excretion is measured at each visit, particularly in patients who had light chains in the urine at presentation. The pattern of the urine M-component was variable, with some patients showing a more indolent behavior, and others showing a very quick increase. A threshold of 500 mg Bence-Jones proteinuria in a 24-h urine specimen seems to be reasonable for the initiation of immediate anti-myeloma therapy.
Another important issue is the development of EMP after autologous SCT. The presence of extramedullary disease at diagnosis was a strong predictor of this feature at relapse/ progression. One previous study showed that up to 45% of patients with extramedullary involvement at diagnosis develop EMPs at the time of relapse. 19 In our series, 38 out of 170 (22%) patients had EMP at the time of diagnosis and 59% of them also had plasmacytomas at first relapse after autologous SCT. A lower incidence of extramedullary relapse ranging from 9 to 14% after autologous SCT has previously been reported. 7, 20, 21 Moreover, the so-called 'isolated extramedullary' relapse was uncommon; only three patients showed this pattern, in spite of the high incidence of EMP at diagnosis in our series. 7 The relapse pattern on the 'transformed' disease, such as plasmablastic myeloma of secondary plasma cell leukemia, was very rare in our series in comparison with previous reports, 7, 20 but was in agreement with a recent study. 18 As previously reported, the recognized dismal prognostic impact of EMP at diagnosis in patients treated with conventional chemotherapy can be overcome with the use of high-dose chemotherapy. 19, 22 Of interest, the presence of this complication at relapse/progression was not significantly associated with a shortened survival in the present study.
The second aspect deals with the significance of the serological progression or relapse vs symptomatic forms. This pattern has received several names, such as insidious 20 or asymptomatic 18 form, in comparison with the symptomatic classical pattern, characterized by anemia, new osteolytic lesions, hypercalcemia, renal failure, EMP, plasma cell leukemia or plasmablastic/lymphoma like. Commonly, relapsed patients respond to conventional chemotherapy such as melphalan-or steroid-based regimens. 20 In our series, patients with asymptomatic relapse/progression showed a clear advantage in terms of OS, reflecting probably more indolent disease biologically, higher chemosensitivity or both. In fact, patients with asymptomatic relapse/progression had more CR and PR rates at the time of first salvage therapy than those with a symptomatic form. The only significant variables associated with OS at the multivariate analysis were the time to relapse, type of relapse (asymptomatic vs symptomatic) and use of salvage second auto-or allogeneic SCT.
An important question is when to begin treatment at the time of first relapse/progression. There is no doubt that in the presence of CRAB symptoms or EMP immediate treatment is needed. 8, 10 For asymptomatic patients, the answer is not so clear. Significant paraprotenemic relapse/progression criteria have been developed by the International Myeloma Working Group, but without any apparent translation into clinical practice yet. 8 Previous aggressive presentation/clinical behavior (renal failure, hypercalcemia), clearly increasing in M-protein, particularly light chains in urine, and decreasing hemoglobin levels should be considered as indicators of early treatment. In our experience, the median time to treatment requirement was only 6 months in the case of serologic relapse/progression. However, in one-fourth of them, treatment can be safely delayed even for more than 2 years. Patients relapsed from CR, particularly those who had ISS 1 or 2 at diagnosis and without significant proteinuria (M-spike lower than 500 mg in 24 h urine) at the time of relapse and with no history of previous EMPs, hypercalcemia and/or renal insufficiency at diagnosis are the most likely to have a longer time until clinical or significant paraproteinemic progression. In contrast, patients progressing from PR or MR or with ISS 3 at diagnosis, that clearly had an increasing M-protein, particularly light chains in urine (500 mg or more), decreasing hemoglobin level, and/or EMPs or renal insufficiency at diagnosis, are the most likely to require therapy when M-protein progression is observed. 10 A real challenge in future will be the early detection of progression in cases presenting with a symptomatic picture. There are almost 50% of the cases in our series accomplishing clinical criteria of relapse/progression, and the response rate and survival was notably reduced. Some attempts with serum biomarkers, such as serum-free light chains, immunophenotype approaches or imaging studies, have been performed. 18, 23 Whether or not some new serological measurements or image tools are useful for early detection and prompt treatment is translated into clinical benefits in this group of patients is still an unsolved question.
In summary, after autologous SCT, serological or asymptomatic relapse/progression is observed in about one half of the patients Progression and relapse in myeloma C Fernández de Larrea et al with MM. The treatment-free interval is longer in patients relapsing from CR than in those progressing from PR. Patients with symptomatic relapse/progression have shorter OS and poorer response to salvage therapy. Relapse pattern is quite similar to the initial clinical presentation. In fact, the small subset with indolent relapse not requiring therapy for at least 2 years had also a more indolent disease at diagnosis. Extramedullary involvement at relapse/progression is frequent, being the highest risk in patients with EMP at diagnosis. Finally, relapse/progression with only extramedullary disease is rare.
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